Short description
PharmaCyte Biotech is a clinical stage biotechnology company focused on developing and preparing to commercialize treatments for cancer.
Description
PharmaCyte Biotech is a clinical stage biotechnology company focused on developing and preparing to commercialize treatments for cancer and diabetes based upon a proprietary cellulose-based live cell encapsulation technology known as Cell-in-a-Box®.
This unique and patented technology will be used as a platform upon which treatments for several types of cancer, including advanced, inoperable pancreatic cancer, and diabetes are being built.
PharmaCyte Biotech’s treatment for pancreatic cancer involves low doses of the well-known anticancer prodrug ifosfamide, together with encapsulated live cells, which convert ifosfamide into its active or “cancer-killing” form.
These capsules are placed as close to the cancerous tumor as possible to enable the delivery of the highest levels of the cancer-killing drug at the source of the cancer. This “targeted chemotherapy” has proven remarkably effective in past clinical trials.
In addition, PharmaCyte Biotech is working towards improving the quality of life for patients with advanced pancreatic cancer and on treatments for other types of solid cancerous tumors. PharmaCyte Biotech is also developing treatments for cancer based upon chemical constituents of marijuana known as cannabinoids.
In doing so, PharmaCyte Biotech is examining ways to exploit the benefits of Cell-in-a-Box® technology in optimizing the anticancer effectiveness of cannabinoids, while minimizing or outright eliminating the debilitating side effects usually associated with cancer treatments.
This provides PharmaCyte Biotech the rare opportunity to develop “green” approaches to fighting deadly cancers, such as those of the pancreas, brain and breast, which affect hundreds of thousands of individuals worldwide every year.
Last funding
Nopepepe
Sign in for full access
Total funding
$$2020202
Sign in for full access
Location
Laguna Hills, California, United States, North America
Founded on
January 1, 1996
Exited on
August 9, 2021
Went public on
August 9, 2021
Stock symbol
PMCB
Non-profit?
No
Acquired?
No
Employees count
1-10
Revenue range
$56378 - 90123
Sign in for full access
Funding rounds count
2
Portfolio organisations count
Nopepepe, No Way
Sign in for full access
Lead investments count
2
Exits count
Noaccess, Absolutely Noaccess
Sign in for full access
IPO exits count
2